Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer

Huanqiang Wang1,Δ, Congying Yang6,Δ, Siyuan Wang2,Δ, Tian Wang1, Jingling Han1, Kai Wei1, Fucun Liu1, Jida Xu1, Xianzhen Peng1,3,✉, Jianming Wang3,4,5,✉

1 Department of Public Health and Preventive Medicine, 2Department of Clinical Medicine, Kangda College of Nanjing Medical University, Lianyungang, Jiangsu 222000, China; 3Department of Epidemiology, 4Department of Social Medicine and Health Education, 5The Innovation Center for Social Risk Governance in Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China; 6Department of Pathology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, China.

Abstract

Identifying sensitive and specific biomarkers for early detection of cancer is immensely imperative for early diagnosis and treatment and better clinical outcome of cancer patients. This study aimed to construct a specific DNA methylation pattern of cancer suppressor genes and explore the feasibility of applying cell-free DNA based methylation as a biomarker for early diagnosis of esophageal squamous cell carcinoma (ESCC). We recruited early stage ESCC patients from Yangzhong County, China. The Illumina Infinium 450K Methylation BeadChip was used to construct a genome-wide DNA methylation profile. Then, differentiated genes were selected for the validation study using the Sequenom MassARRAY platform. The frequency of methylation was compared between cancer tissues, matched cell-free DNAs and normal controls. The specific methylation profiles were constructed, and the sensitivity and specificity were calculated. Seven CG sites in three genes CASZ1, CDH13 and ING2 were significantly hypermethylated in ESCC as compared with normal controls. A significant correlation was found between the methylation of DNA extracted from cancer tissues and matched plasma cell-free DNA, either for individual CG site or for cumulative methylation analysis. The sensitivity and specificity reached 100% at an appropriate cut-point using these specific methylation biomarkers. This study revealed that aberrant DNA methylation is a promising biomarker for molecular diagnosis of esophageal cancer. Hypermethylation of CASZ1, CDH13 and ING2 detected in plasma cell-free DNA can be applied as a potential noninvasive biomarker for diagnosis of esophageal cancer.

Keywords: esophageal neoplasms, DNA methylation, epigenesist, biological markers, tumor suppressor

ΔThese authors contributed equally to this work.
✉Corresponding authors: Xianzhen Peng, Department of Public Health and Preventive Medicine, Kangda College of Nanjing Medical University, Lianyungang, Jiangsu 222000, China. Tel: 86-518-83083544. E-mail: xianzhenpeng@njmu.edu.cn; Jianming Wang, Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China. Tel: 86-25-86868438. E-mail: jnwang@njmu.edu.cn.

Available online at www.jbr-pub.org.cn

© 2018 by the Journal of Biomedical Research. https://doi.org/10.7555/JBR.32.20170065
Introduction

Esophageal cancer is the eighth most common cancer in terms of incidence and ranks sixth in cancer-related deaths worldwide\(^1\). It usually occurs in the middle or upper one-third of the esophagus as the squamous cell carcinoma, or in the lower one-third or junction of the esophagus and stomach as the adenocarcinoma. While esophageal adenocarcinoma has markedly increased in developed countries during last few decades, esophageal squamous cell carcinoma (ESCC) still accounts for a large part, especially in Asian countries\(^3\). In spite of the advances in diagnostic methods and the improvements in surgical techniques and adjuvant chemoradiation therapy, the majority of ESCC are diagnosed at advanced stages with the overall 5-year survival rates of 15\%–50\%\(^4\text{–}^5\). If patients can be diagnosed and treated at an early stage, the 5-year survival rate would reach to 100\% after the endoscopic mucosectomy\(^6\). Therefore, to identify sensitive and specific biomarkers for the early detection of this disease is immensely imperative for the patient’s prognosis.

Carcinogenesis of esophageal cancer is a multifactorial process by the accumulation of heritable changes in both oncogenes and tumor suppressor genes\(^7\). Cancer-related genes may be changed by several genetic mechanisms, which potentially alter the protein encoding nucleotide template, or change the copy number of genes. Epigenetic alteration, comprises heritable changes in gene expression that are not caused by alterations of DNA sequence\(^8\). These epigenetic alterations involve covalent modifications of histones and methylation of cytosine base (C) in the context of CpG dinucleotide within the DNA itself. Epigenetic changes usually occurs early preceding the malignancy\(^9\). A large-scale analysis of DNA methylation changes with tumor cells, making it be an alternative biomarker for human cancers\(^10\text{–}^13\). We recruited 75 esophageal cancer cases who underwent surgery at Yangzhong People’s Hospital between 2012 and 2013. ESCC was pathologically diagnosed in the patients. None of the enrolled patients had received preoperative chemotherapy or radiation therapy. The tumor stage was determined using the Classification of Malignant Tumours Staging System (TNM). Among them, we selected 15 patients during the early stage of ESCC as the study subjects (Supplementary Table 1, available online, and Table 1). The flow chart of the study is in Fig. 1. This study was approved by the ethics committee of Nanjing Medical University. The methods were carried out in accordance with the approved guidelines and a written informed consent was obtained from all participants.

Data collection

Peripheral blood samples were acquired with vacuum blood tubes prior to the treatment. The plasma samples were immediately isolated by centrifugation at 4,000 r/minute for 10 minutes and stored at \(\text{–}70^\circ\text{C}\) until the DNA was extracted. For patients having undergone surgery, tissues in the center of the cancer lesion and remote normal appearing esophagus were excised and stored in \(\text{–}70^\circ\text{C}\) refrigerator immediately. Normal esophageal tissues together with blood samples were collected from healthy individuals who took part in the local health examination program and proved to have no
cancer history and severe esophageal lesions by endoscopy. All healthy subjects provided informed consent to participate in the study.

**DNA extraction**

Genomic DNA was extracted from frozen fresh tissues using the QIAmp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Cell-free DNA was isolated from the 200 μL plasma samples using the QIAmp DNA Blood Mini Kit (Qiagen, Hilden, Germany). The quality and concentration of DNA samples were measured with a Thermo NanoDrop 2000-1 spectrophotometer (NanoDrop Technologies, Montchanin, DE, USA).

**DNA methylation assay**

DNAs were subjected to sodium bisulphite modification using the EZ DNA Methylation kit (Zymo Research, Orange, CA, USA). We measured the aberrant methylation status of DNA samples from ESCC patients based on a two-stage approach. Firstly, we used the Illumina Infinium 450K Methylation BeadChip (Illumina, San Diego, CA, USA) to construct a genome-wide DNA methylation profile. Secondly, differentiated CpG sites were screened by comparing the methylation of cancer and normal tissues. Then, we used the Sequenom MassARRAY platform to perform a quantitative analysis of DNA methylation for specific genes identified from the first stage analysis. This system utilized the base-specific cleavage and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). In brief, after sodium bisulphite modification of DNA samples, the target gene regions were amplified by the Polymerase Chain Reaction (PCR). Primers were derived from Sequenom EpiDesigner platform (www.epidesigner.com) (Table 2). Considering the fragmentation of cell-free DNA, we designed multiple primers to detect methylation of specific sites for plasma samples (Table 3). Subse-

**Table 1** Demographic and baseline information of esophageal squamous cell carcinoma patients in the current study

| Patient No. | Age (years) | Gender | TNM | G (histologic grade) | Tumor location | Stage* |
|-------------|-------------|--------|-----|-----------------------|----------------|-------|
| 1           | 69          | Male   | T2N0M0 | G1                    | Middle         | I     |
| 2           | 47          | Male   | T1N1M0 | G2                    | Lower          | II    |
| 3           | 69          | Male   | T1N0M0 | G2                    | Lower          | I     |
| 4           | 48          | Male   | T3N0M0 | G2                    | Middle         | II    |
| 5           | 63          | Male   | T1N0M0 | G3                    | Middle         | I     |
| 6           | 72          | Female | T2N0M0 | G1                    | Middle         | I     |
| 7           | 69          | Male   | T1N0M0 | G3                    | Lower          | I     |
| 8           | 63          | Female | T1N0M0 | G2                    | Middle         | I     |
| 9           | 64          | Male   | T3N0M0 | G2                    | Middle         | II    |
| 10          | 62          | Male   | T2N0M0 | G1                    | Middle         | I     |

*Tumor stages were evaluated according to the TNM classification of the American Joint Committee on Cancer (AJCC).

![Flow chart of the study](image)

**Fig. 1** Flow chart of the study. ESCC: esophageal squamous cell carcinoma.
### Table 2  Primers designed for detecting DNA methylation in tissues in the current study

| Genes | Forward (5'→3') | Reverse (5'→3') |
|-------|----------------|-----------------|
| ADAMTS9 | aggaagagTATTTTGGAGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctCTCACAACTTACCTTACCA |
| AIM2 | aggaagagTGGAGTTTGGAGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctAAAACCTCTCCCTTACCC |
| CASZ1 | aggaagagGTGGTTTGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctAAAACCTCTCCCTTACCC |
| CDH13 | aggaagagGTGGTTTGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctAAAACCTCTCCCTTACCC |
| EBF3 | aggaagagGTGGTTTGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctAAAACCTCTCCCTTACCC |
| ING2 | aggaagagGTGGTTTGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctAAAACCTCTCCCTTACCC |
| IQGAP2 | aggaagagGTGGTTTGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctAAAACCTCTCCCTTACCC |

### Table 3  Primers designed for detecting cell-free DNA methylation in plasma cell-free DNA in the current study

| Genes | Fragments | Forward (5'→3') | Reverse (5'→3') |
|-------|-----------|----------------|-----------------|
| ADAMTS9 | ADAMTS9-17R | aggaagagTGTGGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctCTCACAACTTACCTTACCA |
| AIM2 | AIM2-5F | aggaagagTGTGGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctCTCACAACTTACCTTACCA |
| CASZ1 | aggaagagGTGGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctCTCACAACTTACCTTACCA |
| CDH13 | CDH13-17F | aggaagagTGTGGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctCTCACAACTTACCTTACCA |
| EBF3 | EBF3-1F | aggaagagTGTGGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctCTCACAACTTACCTTACCA |
| ING2 | aggaagagTGTGGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctCTCACAACTTACCTTACCA |
| IQGAP2 | IQGAP2-1F | aggaagagTGTGGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctCTCACAACTTACCTTACCA |
| KLF6 | KLF6-2F | aggaagagTGTGGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctCTCACAACTTACCTTACCA |
| TMEFF2 | TMEFF2-9F | aggaagagTGTGGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctCTCACAACTTACCTTACCA |
| TRIT1 | TRIT1-3F | aggaagagTGTGGTTTGTGGTAGGTTAG | cagtaatacgactcctatagggagaaggctCTCACAACTTACCTTACCA |
quently, unincorporated dNTPs left over were neutralized by dephosphorylation using the shrimp alkaline phosphatase. By tagging the reverse PCR primer with the T7 recognition sequence, a single-stranded RNA copy of the template was generated by *in vitro* transcription. After base specific (U-specific) cleavage by RNase A, the cleavage products were analyzed using MassARRAY. Signals with a 16 Da shift were representative for methylation events, and signal intensity was correlated with the degree of DNA methylation[28]. The methylation status ranged from 0 (completely unmethylated) to 1 (completely methylated).

**Statistical analysis**

Data generated from the 450K DNA Methylation BeadChip were visualized and analyzed using the GenomeStudio Software version 2011.1 (Illumina). Each CpG site on the BeadChip was represented by two bead types representing the methylated (M) and unmethylated (U) state at that site. The methylation value for each CpG locus was expressed as a β value[29]. We calculated the diffScore by taking into account the background noise and sample variability. Individual CpG site was determined statistically significant based on two criteria: (1) absolute diffScore measured using the Illumina custom model and adjusted for the multiple comparisons was greater than 15; and (2) degree of difference measured by the changes in β value (Δβ) was greater than 0.31 (corresponding to an average of 31% or greater methylation difference). Δβ = (βnormal − βmutant). DiffScore = 10 Sigh (βnormal − βmutant) log10P. Hierarchical unsupervised clustering analysis was used to draw heat maps of specific sites by comparing normal and tumor tissues. The pathway and function analysis were performed using KEGG and Gene Ontology (GO). Data generated from Sequenom MassARRAY platform were analyzed using IBM SPSS Statistics 18.0 (IBM Corp., NY, USA). We not only considered the methylation status of individual CpG site, but also calculated the cumulative methylation of multiple CpG sites in specific genes using additive models. The correlation of methylation between tumor tissues and matched plasma samples was analyzed using correlation analysis.

**Results**

**Identification of differentially methylated CpG sites**

Using the Infinium Methylation 450K array, we evaluated the methylation status of five paired tumor samples and corresponding adjacent normal-appearing tissues from ESCC patients, along with two normal esophageal tissue samples from the healthy population. A total of 173 CpG sites showed statistical significance with the absolute diffScore≥15 and Δβ≥0.31 between ESCC and normal esophageal tissue samples. Then we sorted CpG sites by the diffScore and defined another 200 CpGs. After removing duplications, a total of 354 CpG sites remained for analysis. We drafted a heat map illustrating the cluster of these 354 CpG sites in our previous study[30]. The heat map compared the methylation between tumor and normal tissues and showed a significantly differentiated pattern. However, in our previous study, we only focused on the methylation of promoter regions. In combination with the KEGG pathway and GO analysis, we identified ten genes in the other regions for the next-step validation study (*Table 4*). The KEGG pathway analysis showed that IQGAP2 and TRIT1 were involved in the regulation of actin cytoskeleton and metabolic pathways, respectively. The functions of these ten genes based on GO analyses were listed in Supplementary Table 2 (available online).

### Table 4 The information of selected genes

| Genes  | Chromosome location     | Start    | Stop      | Length (kb) | Position   |
|--------|-------------------------|----------|-----------|-------------|------------|
| ADAMTS9| 3p14.3-p14.2            | 64598534 | 64770557  | 172024      | 3' UTR     |
| AIM2   | 1q22                    | 159032275| 15904647  | 14373       | 5' UTR     |
| CASZ1  | 1p36.22                 | 10696661 | 10856707  | 160047      | Intron     |
| CDH13  | 16q24.2-q24.3           | 82660578 | 83830201  | 1169624     | Intron     |
| EBF3   | 10q26.3                 | 131633547| 131762091 | 128545      | Intron     |
| ING2   | 4q35.1                  | 184426220| 184432249 | 6030        | Intron     |
| IQGAP2 | 5q13.3                  | 75699149 | 76003957  | 304809      | Intron     |
| KLF6   | 10p15                   | 3821234  | 3827455   | 6222        | 3' UTR     |
| TMEFF2 | 2q32.3                  | 192814743| 193059644 | 244902      | Intron     |
| TRIT1  | 1p35.3-p34.1            | 40306703 | 40349177  | 42475       | TSS1500    |

Wang H et al. J Biomed Res, 2018, 32(6)
Validation of methylation levels of specific genes

We further validated the methylation levels of specific CpG sites of these ten genes by comparing 10 ESCC tissues, 10 matched peripheral plasma samples and 3 normal esophageal tissues from healthy individuals. Individual CpG site analysis showed that CASZ1_CpG_2–3, CASZ1_CpG_4, CASZ1_CpG_5, CDH13_CpG_8, ING2_CpG_1.2.3.4, ING2_CpG_5 and ING2_CpG_6.7 were significantly hypermethylated in ESCC tissues as compared with controls (Table 5). The cumulative effect analyses by considering multiple CpG sites in each gene also demonstrated an obvious difference of methylation levels between normal and cancer samples (CASZ1: \( P < 0.001 \), CDH13: \( P < 0.001 \), ING2: \( P < 0.001 \) (Table 6)). Interestingly, the similar difference was also observed in ESCC plasma as compared with controls (Table 5 and Table 6). Moreover, the frequency of methylation in individual CpG site or the cumulative methylation in each gene was higher in plasma samples than that detected in cancer tissue samples.

Correlation of methylation between tumor tissue and plasma sample

A significant correlation was found between the methylation of DNA extracted from esophageal cancer tissues and cell-free DNA extracted from the matched plasmas, either for individual CpG site analysis \( (r = 0.460, P < 0.001, \text{ Fig. 2}) \) or for cumulative effect analysis on multiple CpG sites in each specific gene \( (r = 0.730, P < 0.001, \text{ Fig. 3}) \).

Evaluation of circulating cell-free DNA methylation for diagnosing ESCC

To assess the clinical usefulness of plasma cell-free DNA methylation as diagnostic biomarkers for ESCC, we calculated the sensitivity and specificity together with the receiver operating characteristic (ROC) curve. If we adopted the above-mentioned seven CpG sites in three cancer specific genes, the sensitivity and specificity were all reached to100\% at an appropriate cut-point (Table 7 and Supplementary Table 3, available online). The area under the curve (AUC) of ROC was 1 either using the individual CpG site or cumulative methylation of multiple CpG sites in specific genes.

Discussion

Along with the genetic variants, aberrant methylation is another predominant mechanism inactivating tumor suppressor genes during the carcinogenesis. In this study, we demonstrate a specific DNA methylation

| Table 5 | Methylation of individual CG sites in specific genes in esophageal cancer patients and normal controls |
|---------|--------------------------------------------------------------------------------------------------|
| CG sites | Plasma [\( (n = 10) \)] | Tissue [\( (n = 10) \)] | Control [\( (n = 3) \)] | \( P \) value (plasma vs. control) | \( P \) value (tissue vs. control) |
| CASZ1   | 95.00(93.88–96.12) | 88.20(84.95–91.45) | 73.33(55.71–90.96) | <0.001 | <0.001 |
| CASZ1_CpG_2–3 | 93.80(92.72–94.75) | 86.30(82.96–85.94) | 71.43(55.71–84.55) | <0.001 | <0.001 |
| CASZ1_CpG_4 | 83.40(77.21–89.59) | 76.60(69.26–83.94) | 48.33(37.13–59.53) | <0.001 | <0.001 |
| CASZ1_CpG_5 | 78.60(72.36–84.84) | 71.10(65.63–76.57) | 50.33(33.79–66.87) | <0.001 | <0.001 |
| CDH13   | 98.00(96.35–99.65) | 77.80(66.50–89.10) | 37.00(19.61–54.39) | <0.001 | <0.001 |
| ING2    | 93.80(89.65–97.95) | 52.60(36.36–68.84) | 21.00(1.28–40.72) | 0.011 | <0.001 |
| ING2_CpG_1.2.3.4 | 83.80(69.86–97.74) | 55.30(39.64–70.96) | 24.67(8.50–40.83) | 0.046 | <0.001 |
| ING2_CpG_5 | 83.80(69.86–97.74) | 55.30(39.64–70.96) | 24.67(8.50–40.83) | 0.046 | <0.001 |
| ING2_CpG_6.7 | 95.50(92.88–98.12) | 60.80(45.21–76.39) | 28.00(6.34–49.66) | 0.006 | <0.001 |

| Table 6 | Cumulative methylation of specific genes in esophageal cancer patients and control subjects |
|---------|--------------------------------------------------------------------------------------------------|
| Genes   | Plasma [\( (n = 10) \)] | Tissue [\( (n = 10) \)] | Control [\( (n = 10) \)] | \( P \) value (plasma vs. control) | \( P \) value (tissue vs. control) |
| CASZ1   | 4.21(4.02–4.40) | 3.88(3.56–4.20) | 2.97(2.38–3.55) | 0.001 | <0.001 |
| CDH13   | 3.20(2.82–3.58) | 2.32(1.82–2.82) | 1.27(0.62–1.93) | 0.024 | <0.001 |
| ING2    | 2.73(2.60–2.86) | 1.69(1.21–2.16) | 0.74(0.17–1.31) | 0.009 | <0.001 |

* Cumulative methylation was calculated by summing up the frequency of individual CpG sites in each gene.
pattern of tumor-related genes for ESCC. The consistency of methylation between cancer tissues and plasma indicates that cell-free DNA methylation profile can be a promising biomarker for the diagnosis of esophageal cancer.

We used the Infinium Human Methylation 450K BeadChip to screen for differentiated CpG sites between esophageal cancer and normal control tissues. This BeadChip allows researchers to interrogate more than 485,000 methylation sites per sample at single-nucleotide resolution. It has emerged as one of the preferred methodologies to study genome-wide DNA methylation because of its optimal combination of genome-wide coverage (96% of CpG islands and 99% of RefSeq genes), comprehensive representation of functional gene sub-regions, and good reproducibility across other platforms, and relative affordability[31].

Based on the genome-wide DNA methylation data, 10 specific tumor suppressor genes were selected for the validation study. Among them, seven CpG sites from three genes (CASZ1, CDH13 and ING2) were significantly hypermethylated in ESCC tissues. CASZ1 is a zinc finger transcription factor which is critical for controlling the normal differentiation of subtypes of neural and cardiac muscle cells[32]. It inhibits cell cycle progression in neuroblastoma by restoring pRb activity[33]. Loss of CASZ1 function is associated with a poor prognosis of the disease[32]. CDH13, a member of the cadherin gene superfamily has been mapped to 16q24, a locus that frequently undergoes deletion in human cancers[20]. As a candidate tumor suppressive gene, ING2 is frequently decreased expression in human tumors[34]. Nonphysiological overexpression of ING2 induces apoptosis and cell cycle arrest via p53 modification[35]. Aberrant methylation of these genes can alter their normal function, resulting in the carcinogenesis of ESCC[36].

DNA methylation has been regarded as the most robust epigenetic mark. Almost any biological tissue sample or body fluid can be used for analyzing DNA methylation[37]. Tumor biopsies can be sampled in most cancers but are often difficult to obtain. For the early detection of cancers, only peripheral, easy-to-access tissues or bodily fluids can be collected. These samples include peripheral blood, saliva, urine, stools or bronchial aspirates, etc[37–38].

Cell-free circulating tumor DNA is a potential surrogate for the entire tumor genome[39]. It has been estimated that more than 90% of the total circulating cell-free DNA is derived from the tumor tissue[40]. The release of nucleic acids into the blood is thought to be related to the apoptosis and necrosis of cancer cells in the tumor microenvironment[26]. Changes in the levels of circulating nucleic acids are associated with tumor burden and malignant progression. The presence of methylated DNA in the serum or plasma have been found in various types of malignancy, including bladder cancer, breast cancer, cervical cancer, colorectal cancer, lung cancer, and prostate cancer[41].

Interestingly, cell-free circulating DNA methylation profiles are in high concordance with patterns observed in corresponding primary tumor tissues[29,42]. It has been linked to different types of cancer[17,29,43]. In our study, we confirmed a significant correlation of methylation patterns of tumor suppressor genes between plasma samples and matched tumor tissues. We could find that the r for cumulative effect analysis on multiple

Fig. 2 Scatter plot of individual CG site methylation in esophageal cancer tissue and plasma cell-free DNA. T indicates cancer tissue, S indicates plasma cell-free DNA.

Fig. 3 Scatter plot of cumulative methylation detected in esophageal cancer tissue and plasma cell-free DNA. T indicates cancer tissue, S indicates plasma cell-free DNA.
CpG sites in each specific gene was high for the individual CpG site analysis. And the fact that sites separated by less than 1 kb show highly correlated methylation[^44–46], suggesting that our analysis of cumulative effect on multiple CpG sites in each specific gene may capture more accurate methylation information near transcription start sites. Moreover, we observed that the methylation level of specific genes detected in plasma samples was higher than that in tumor tissues. This may be attributed to the heterogeneous mix of different cell types in the tumor tissues[^47]. An accurate correlation of molecular and morphologic pathologies requires the ability to procure pure populations of morphologically similar cells for molecular analysis. Several approaches have been developed to address this problem, with laser capture microdissection (LCM) emerging as one of the methods of choice for isolating highly pure cells from a

| CG site          | Cut-point | Sensitivity (%) | Specificity (%) | Correctly classified (%) |
|------------------|-----------|-----------------|-----------------|--------------------------|
| CASZ1_CPG_23     | 0.67      | 100.00          | 0.00            | 76.92                    |
|                  | 0.72      | 100.00          | 33.33           | 84.62                    |
|                  | 0.81      | 100.00          | 66.67           | 92.31                    |
|                  | 0.92      | 100.00          | 100.00          | 100.00                   |
|                  | 0.93      | 80.00           | 100.00          | 84.62                    |
|                  | 0.94      | 70.00           | 100.00          | 76.92                    |
|                  | 0.95      | 50.00           | 100.00          | 61.54                    |
|                  | 0.96      | 10.00           | 100.00          | 30.77                    |
|                  | 0.97      | 0.00            | 100.00          | 23.08                    |
| CASZ1_CPG_4      | 0.44      | 100.00          | 0.00            | 76.92                    |
|                  | 0.48      | 100.00          | 33.33           | 84.62                    |
|                  | 0.53      | 100.00          | 66.67           | 92.31                    |
|                  | 0.63      | 100.00          | 100.00          | 100.00                   |
|                  | 0.73      | 80.00           | 100.00          | 84.62                    |
|                  | 0.83      | 70.00           | 100.00          | 76.92                    |
|                  | 0.86      | 60.00           | 100.00          | 69.23                    |
|                  | 0.87      | 40.00           | 100.00          | 53.85                    |
|                  | 0.88      | 20.00           | 100.00          | 38.46                    |
|                  | 0.89      | 0.00            | 100.00          | 23.08                    |
|                  | 0.46      | 100.00          | 0.00            | 76.92                    |
| CASZ1_CPG_5      | 0.47      | 100.00          | 33.33           | 84.62                    |
|                  | 0.58      | 100.00          | 66.67           | 92.31                    |
|                  | 0.63      | 100.00          | 100.00          | 100.00                   |
|                  | 0.65      | 80.00           | 100.00          | 84.62                    |
|                  | 0.75      | 70.00           | 100.00          | 76.92                    |
|                  | 0.76      | 60.00           | 100.00          | 69.23                    |
|                  | 0.83      | 20.00           | 100.00          | 38.46                    |
|                  | 0.87      | 10.00           | 100.00          | 30.77                    |
|                  | 0.88      | 0.00            | 100.00          | 23.08                    |
| CDH13_CPG_8      | 0.29      | 100.00          | 0.00            | 76.92                    |
|                  | 0.40      | 100.00          | 33.33           | 84.62                    |
|                  | 0.42      | 100.00          | 66.67           | 92.31                    |
|                  | 0.92      | 100.00          | 100.00          | 100.00                   |
|                  | 0.98      | 90.00           | 100.00          | 92.31                    |
|                  | 1.00      | 30.00           | 100.00          | 46.15                    |

| CG site          | Cut-point | Sensitivity (%) | Specificity (%) | Correctly classified (%) |
|------------------|-----------|-----------------|-----------------|--------------------------|
| ING2_CPG_1234    | 0.12      | 100.00          | 0.00            | 76.92                    |
|                  | 0.24      | 100.00          | 33.33           | 84.62                    |
|                  | 0.27      | 100.00          | 66.67           | 92.31                    |
|                  | 0.86      | 100.00          | 100.00          | 100.00                   |
|                  | 0.89      | 60.00           | 100.00          | 69.23                    |
|                  | 0.94      | 50.00           | 100.00          | 61.54                    |
|                  | 0.96      | 40.00           | 100.00          | 53.85                    |
|                  | 0.99      | 20.00           | 100.00          | 38.46                    |
|                  | 1.00      | 0.00            | 100.00          | 23.08                    |
| ING2_CPG_5       | 0.18      | 100.00          | 0.00            | 76.92                    |
|                  | 0.25      | 100.00          | 33.33           | 84.62                    |
|                  | 0.31      | 100.00          | 66.67           | 92.31                    |
|                  | 0.32      | 100.00          | 100.00          | 100.00                   |
|                  | 0.73      | 80.00           | 100.00          | 84.62                    |
|                  | 0.87      | 70.00           | 100.00          | 76.92                    |
|                  | 0.88      | 60.00           | 100.00          | 69.23                    |
|                  | 0.89      | 50.00           | 100.00          | 61.54                    |
|                  | 0.90      | 30.00           | 100.00          | 46.15                    |
|                  | 0.93      | 0.00            | 100.00          | 23.08                    |
|                  | 0.18      | 100.00          | 0.00            | 76.92                    |
|                  | 0.32      | 100.00          | 33.33           | 84.62                    |
|                  | 0.34      | 100.00          | 66.67           | 92.31                    |
|                  | 0.86      | 100.00          | 100.00          | 100.00                   |
|                  | 0.93      | 80.00           | 100.00          | 84.62                    |
|                  | 0.96      | 50.00           | 100.00          | 61.54                    |
|                  | 0.97      | 30.00           | 100.00          | 46.15                    |
|                  | 0.98      | 0.00            | 100.00          | 23.08                    |
heterogeneous tissue section[48]. However, the invasive feature of tissue biopsy has restricted its clinical use. In this case, the blood-based assay has the advantage of using specimens which have been collected with a far less invasive procedure.

Despite the possible use as a marker for cancer diagnosis or progression, the limited quantities of cell-free DNA in the plasma affected its wide application. An increasing tendency to harmonize appropriate methods for DNA methylation detection and reference standards will accelerate the development of DNA methylation as biomarkers for cancer detection. Though several techniques such as MethyLight qPCR, MethyLight digital PCR (dPCR), methylation-sensitive and-independent restriction enzyme (MSRE/MDRE) digestion followed by qPCR or dPCR, and bisulfite amplification next generation sequencing (NGS) have been developed, there is currently a lack of consensus regarding the optimal methodologies to quantify methylation status[49]. Considering the fragmentation of cell-free DNA and the degradation by sodium bisulphite modification, a more sensitive and specific method is essential for clinical use of cell-free DNA methylation detection in the future.

In conclusion, aberrant methylatedDNAs can be promising and valuable biomarkers for molecular diagnosis of esophageal cancer. Hypermethylation of CASZ1, CDH13 and ING2 genes detected using cell-free DNA in blood samples can be applied as a potential biomarker for the diagnosis of esophageal cancer.

Acknowledgments

This work was supported by the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (grant number 17KJD330002); the Science and Technology Development Fund of Nanjing Medical University (grant number 2017NJMUZD141) and the Science and Technology Development Fund of Nanjing Medical University of China (grant number 17KJD330002); the Science Foundation of the Jiangsu Higher Education Institutions (grant number 14KJA430004). The funding agencies had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript.

References

[1] Zhang Y. Epidemiology of esophageal cancer[J]. World J Gastroenterol, 2013, 19(34): 5598–5606.
[2] Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma[J]. Lancet, 2013, 381(9864): 400–412.
[3] Vizcaíno AP, Moreno V, Lambert R, et al. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1999[J]. Int J Cancer, 2002, 99(6): 860–868.
[4] Rutegård M, Charonis K, Lu Y, et al. Population-based esophageal cancer survival after resection without neoadjuvant therapy: an update[J]. Surgery, 2012, 152(5): 903–910.
[5] van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22): 2074–2084.
[6] Wang GQ. 30-year experiences on early detection and treatment of esophageal cancer in high risk areas[J]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2001, 23(1): 69–72.
[7] Sandoval J, Esteller M. Cancer epigenomics: beyond genomics[J]. Curr Opin Genet Dev, 2012, 22(1): 50–55.
[8] Gronbaek K, Hother C, Jones PA. Epigenetic changes in cancer[J]. APMIS, 2007, 115(10): 1039–1059.
[9] Dejeux E, Audard V, Cavard C, et al. Rapid identification of promoter hypermethylation in hepatocellular carcinoma by pyrosequencing of etiologically homogeneous sample pools[J]. J Mol Diagn, 2007, 9(4): 510–520.
[10] Baba Y, Watanabe M, Baba H. Review of the alterations in DNA methylation in esophageal squamous cell carcinoma[J]. Surg Today, 2013, 43(12): 1355–1364.
[11] Li JS, Ying JM, Wang XW, et al. Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma[J]. Chin J Cancer, 2013, 32(1): 3–11.
[12] Kaz AM, Grady WM. Epigenetic biomarkers in esophageal cancer[J]. Cancer Lett, 2014, 342(2): 193–199.
[13] Guo M, Ren J, House MG, et al. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus[J]. Clin Cancer Res, 2006, 12(15): 4515–4522.
[14] Taghavi N, Biramijamal F, Sotoudeh M, et al. p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma[J]. BMC Cancer, 2010, 10: 138.
[15] Hibi K, Taguchi M, Nakayama H, et al. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma[J]. Clin Cancer Res, 2001, 7(10): 3135–3138.
[16] Zhang L, Lu W, Miao X, et al. Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma[J]. Carcinogenesis, 2003, 24(6): 1039–1044.
[17] Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma[J]. J Natl Cancer Inst, 2000, 92(22): 1805–1811.
[18] Noguchi T, Takeno S, Kimura Y, et al. FHIT expression and hypermethylation in esophageal squamous cell carcinoma[J]. Int J Mol Med, 2003, 11(4): 441–447.
[19] Kuroki T, Trapasso F, Yendamuri S, et al. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in
esophageal squamous cell carcinoma[J]. *Cancer Res*, 2003, 63 (13): 3724–3728.

[20] Jin Z, Cheng Y, Olanu A, et al. Promoter hypermethylation of CDH13 is a common, early event in human esophagealadenocarcinogenesis and correlates with clinical risk factors[J]. *Int J Cancer*, 2008, 123(10): 2331–2336.

[21] Shibata Y, Haruki N, Kuzawara Y, et al. Chfr expression isdownregulated by CpG island hypermethylation in esophageal cancer[J]. *Carcinogenesis*, 2002, 23(10): 1695–1699.

[22] Jin Z, Mori Y, Hamilton JP, et al. Hypermethylation of thesomatostatin promoter is a common, early event in human esophageal carcinogenesis[J]. *Cancer*, 2008, 112(1): 43–49.

[23] Chan KC, Jiang P, Chan CW, et al. Noninvasive detection of tumor-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing[J]. *Proc Natl Acad Sci U S A*, 2013, 110(47): 18761–18768.

[24] Hattori N, Ushijima T. Compendium of aberrant DNA methylation and histone modifications in cancer[J]. *Biochim Biophys Acta*, 2004, 1655(1–2): 3–9.

[25] Nie K, Jia Y, Zhang X. Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer[J]. *Tumour Biol*, 2015, 36(1): 7–9.

[26] Li X, Zhou F, Jiang C, et al. Identification of a DNA methylome profile of esophageal squamous cell carcinoma and potential plasma epigenetic biomarkers for early diagnosis[J]. *PLoS One*, 2014, 9(7): e103162.

[27] Wang JM, Xu B, Hsieh CC, et al. Longitudinal trends of stomach cancer and esophageal cancer in Yangzhong County: a high-incidence rural area of China[J]. *Eur J Gastroenterol Hepatol*, 2005, 17(12): 1339–1344.

[28] Gaedcke J, Leha A, Claus R, et al. Identification of a DNA methylation signature to predict disease-free survival in locally advanced rectal cancer[J]. *Oncotarget*, 2014, 5(18): 8123–8135.

[29] Zhai R, Zhao Y, Su L, et al. Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus[J]. *Neoplasia*, 2012, 14(1): 29–33.

[30] Peng X, Xue H, Lü L, et al. Accumulated promoter methylation as a potential biomarker for esophageal cancer[J]. *Oncotarget*, 2017, 8(1): 679–691.

[31] Yousefi P, Huen K, Aguilar Schall R, et al. Considerations for normalizaton of DNA methylation data by Illumina 450K BeadChip assay in population studies[J]. *Epigenetics*, 2013, 8 (11): 1141–1152.

[32] Virden RA, Thiele CJ, Liu Z. Characterization of critical domains within the tumor suppressor CASZ1 required for transcriptional regulation and growth suppression[J]. *Mol Cell Biol*, 2012, 32(8): 1518–1528.

[33] Liu Z, Rader J, He S, et al. CASZ1 inhibits cell cycle progression in neuroblastoma by restoring pRb activity[J]. *Cell Cycle*, 2013, 12(14): 2210–2218.

[34] Larricue D, Ythier D, Brambilla C, et al. ING2 controls the G1 to S-phase transition by regulating p21 expression[J]. *Cell Cycle*, 2010, 9(19): 3984–3990.

[35] Li X, Kikuchi K, Takano Y. ING genes work as tumor suppressor genes in the carcinogenesis of head and neck squamous cell carcinoma[J]. *J Oncol*, 2011, 2011: 963614.

[36] Adalsteinsson BT, Ferguson-Smith AC. Epigenetic control of the genome-lessons from genomic imprinting[J]. *Genes (Basel)*, 2014, 5(3): 635–655.

[37] Mikeska T, Craig JM. DNA methylation biomarkers: cancerand beyond[J]. *Genes (Basel)*, 2014, 5(3): 821–864.

[38] Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrantpromoter methylation in bronchial epithelium and sputum fromcurrent and former smokers[J]. *Cancer Res*, 2002, 62(8): 2370–2377.

[39] Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquidbiopsy for cancer[J]. *Clin Chem*, 2015, 61(1): 112–123.

[40] Jahr S, Hentze H, Englisch S, et al. DNA fragments in the bloodplasma of cancer patients: quantitations and evidence for theirorigin from apoptotic and necrotic cells[J]. *Cancer Res*, 2001, 61(4): 1659–1665.

[41] Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acidsas biomarkers in cancer patients[J]. *Nat Rev Cancer*, 2011, 11(6): 426–437.

[42] Radpour R, Barekati Z, Kohler C, et al. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer[J]. *PLoS One*, 2011, 6(1): e16080.

[43] Liggett TE, Melnikov AA, Marks JR, et al. Methylationsignatures in cell-free plasma DNA reflect removal of the primarytumor and drug treatment of breast cancer patients[J]. *Int J Cancer*, 2011, 128(2): 492–499.

[44] Fraser HB, Lam LL, Neumann SM, et al. Population specificityof human DNA methylation[J]. *Genome Biol*, 2012, 13(2): R8.

[45] Li Y, Zhu J, Tian G, et al. The DNA methylome of human peripheral blood mononuclear cells[J]. *PLoS Biol*, 2010, 8(11): e1000533.

[46] Eckhardt F, Lewin J, Cortese R, et al. DNA methylationprofiling of human chromosomes 6, 20 and 22[J]. *Proc Natl Acad Sci U S A*, 2011, 108(13): 5353–5358.

[47] Zanni KL, Chan GK. Laser capture microdissection: under-standing the techniques and implications for molecular biology in nursing research through analysis of breast cancer tumor samples[J]. *J Biomed Res*, 2011, 13(3): 297–305.

[48] Craven RA, Banks RE. Laser capture microdissection andproteomics: possibilities and limitation[J]. *Proteomics*, 2001, 1(10): 1200–1204.

[49] Redshaw N, Huggett JF, Taylor MS, et al. Quantification ofepigenetic biomarkers: an evaluation of established and emerging methods for DNA methylation analysis[J]. *BMC Genomics*, 2014, 15(1): 1174.